STI Stock Trade Intelligence
CU6

Clarity Pharmaceuticals Ltd

Health Care · ASX:CU6
$1.82
▲ +0.55%
Market cap
$681M
Turnover
$8,173,758
Last price
$1.82
Day change
+0.55%
Announcements
15
Range, past year
Open 4.060 · Low 1.340 · Now 1.825 · High 5.870
Open CU6 in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

CU6 momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
39/100
Wyckoff phase
Accumulation1d
Trend stage
Neutral
1 Day
+0.6%
1 Week
+16.2%
1 Month
-2.1%
1 Year
-53.0%
RSI
53
Avg daily range
9.2%

Clarity Pharmaceuticals Ltd scores 39 out of 100 for momentum quality, a reading rated low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 1 trading day. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently outperforming and the institutional accumulation signal reads low.

What stands out
  • Trend R² 0.82 — highly linear uptrend
  • MACD histogram positive & rising
Points to watch
  • 60d drawdown -45.0%
  • High volatility (ATR 9.2%)
  • Risk rating: Very High
  • Composite downside risk elevated
CU6 appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

CU6 announcements

Recent price-sensitive releases.
  • 2026-11-12 First FDA Breakthrough Therapy designation in PSMA PET Trading Halt Lifted | Progress Report
  • 2026-11-11 Trading Halt Trading Halt
  • 2026-11-11 Pause in Trading Notice Pending
  • 2026-10-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-27 Ph III CLARIFY trial target number of participants achieved Progress Report
  • 2026-10-08 SECuRE update Progress Report
  • 2026-08-27 Preliminary Final Report Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.